Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor

Details Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor

2006-05-02

2006-05-02

Davis, Zinna Northington (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C514S256000, C514S357000, C514S365000, C514S374000, C514S378000, C514S406000, C514S438000, C544S335000, C546S286000, C546S336000, C548S145000, C548S215000, C548S240000, C548S265800, C549S029000

Reexamination Certificate

active

07037927

ABSTRACT:
The present invention relates to compounds of formula (I)that are novel VR1 antagonists useful in treating pain, inflammatory thermal hyperalgesia, urinary incontinence, or bladder overactivity.

REFERENCES:
patent: 6462036 (2002-10-01), Doyle et al.
patent: 533267 (1992-09-01), None
patent: 0 513 379 (1992-11-01), None
patent: 0 533 267 (1993-03-01), None
patent: 896821 (1999-02-01), None
patent: 2001-139550 (2001-05-01), None
patent: 90/09989 (1990-09-01), None
patent: 93/16053 (1993-08-01), None
patent: 95/04729 (1995-02-01), None
patent: 00/06085 (2000-02-01), None
patent: WO 00/46203 (2000-08-01), None
patent: WO 00/78726 (2000-12-01), None
patent: 02/10146 (2002-02-01), None
patent: 03/003008 (2003-01-01), None
patent: WO 03/027081 (2003-04-01), None
patent: 2004/009563 (2004-01-01), None
patent: 2004/056347 (2004-07-01), None
patent: 2004/056774 (2004-07-01), None
Basha et al, J. Chem. Soc., Chem. Commun., vol. 4, pp. 305-306, 1987.
Fujisawa Pharmaceutical Co., Ltd, CA 132: 49960, 1999 of JP 11349572.
Abromovitch et al., “Arylpyridines, Part I. Orientation in the reaction of phenyllithium with some 3-substituted pyridines,” Can. J. Chem. 38:761-771 (1960).
Caterina et al., “Impaired nociception and pain sensation in mice lacking the capsaicin receptor,” Science 288:306-313 (2000).
Caterina et al., “The capsaicin receptor: a heat-activated ion channel in the pain pathway,” Nature 289:816-824 (1997).
Caterina et al., “The vanilloid receptor: a molecular gateway to the pain pathway,” Annu. Rev. Neurosci. 24:487-517 (2001).
Collier et al., “The abdominal constriction response and its suppression by analgesic drugs in the mouse,” Br. J. Pharmac. Chemother. 32:295-310 (1968).
Davis et al., “Vanilloid receptor-1 is essential for inflammatory thermal hyperalgesia,” Nature 405:183-187 (2000).
Fowler, “Intravesical treatment of overactive bladder,” Urology 55(Supp. 5A):60-64 (2000).
Hayes et al., “Cloning and functional expression of a human orthologue of rat vanilloid receptor-1,” Pain 88:205-215 (2000).
Jones, “The synthesis of some amines and amino acids containing the pyrazole nucleus,” J. Am. Chem. Soc. 71:3994-4000 (1949).
Loew, Chem. Ber. 23:1452 (1890).
Nolano et al., “Topical capsaicin in humans: parallel loss of epidermal nerve fibers and pain sensation,” Pain 81:135-145 (1999).
Bachmann, W.E. & Barton, S.M.X., “The Relative Proportions of Stereoisomeric Oximes Formed in the Oximation of Unsysmmetrical Ketones”,Journ of Organic Chem.,3:300-311 (1938).
Beer, P.D., et al., “New Classes of Anion Receptor containing Charged and Neutral Transition Metal Lewis Acidic Recognition Sites”,Journ of the Chem Soc, Chem. Comm.,10:828-830 (1993).
Cain, B.F., et al., “Potential Antitumor Agents. Ix. Bisquaternary Salts”,Journ of Medic Chem.,11(5):963-966 (1968).
Eric, B., et al., “Über eineSynthese von Pyridin-ketonen . . . ”Berichte der Deutschen Chemischen Gesellschaft,57:828-834 (1924).
Hales, N.J. & Beattie, J.F., “Novel Inhibitors of Prolyl 4-Hydroxylase. T. The Intriguing Structure-Activity Relationships Seen with 2,2'-Bipyridine and its 5,5'-Dicarboxylic Acid Derivatives”,J Med Chem., 36:3853-3858 (1992).
Accession No.: 2142678, Dataase Crossfire Beilstein Beilstein Institut Zur Foederung Der Chemischen Wissenschaften, Frankfurt AM Main.

Affiliated with

Also associated with

Rating

Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Amides that inhibit vanilloid receptor subtype 1 (VR1) receptor will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3544446